Pharmaceutical Import Guide 2026: FDA Drug Registration & DEA Requirements

Why Pharmaceutical Imports Are Heavily Regulated

Pharmaceuticals are among the most strictly regulated product categories in US import law. Unlike most goods, where US Customs and Border Protection (CBP) is the primary gatekeeper, pharmaceutical imports involve at minimum two federal agencies — the Food and Drug Administration (FDA) and, for controlled substances, the Drug Enforcement Administration (DEA). Both operate independently, and clearance from one does not imply clearance from the other.

The regulatory framework reflects the unique public health stakes: adulterated, misbranded, or counterfeit pharmaceuticals can injure or kill patients. FDA's authority derives primarily from the Federal Food, Drug, and Cosmetic Act (FD&C Act), codified at 21 USC 301 et seq. The DEA's authority over controlled substances derives from the Controlled Substances Act (CSA), codified at 21 USC 801 et seq.

The practical consequence for importers is substantial: a pharmaceutical product that meets all CBP tariff requirements and clears customs entry may still be detained and refused admission at the port because the manufacturing facility is unregistered, lacks current cGMP certification, or appears on an FDA import alert. Understanding the regulatory sequence — and where in that sequence your products may face scrutiny — is essential before committing to any foreign pharmaceutical supply relationship.

The three-agency framework — FDA, DEA, CBP — creates distinct compliance tracks that must all be satisfied simultaneously. A shipment may be released by CBP yet detained by FDA; a facility may have valid FDA registration yet face DEA quota restrictions that prevent legal importation of a specific substance. Experienced pharmaceutical importers manage these compliance tracks in parallel, not sequentially.

---

FDA Drug Establishment Registration (21 CFR Part 207)

The foundational requirement for any foreign pharmaceutical manufacturer seeking to export drugs to the US is establishment registration with FDA under 21 CFR Part 207. This is not optional, not conditional on shipment size, and not waivable. An unregistered foreign drug manufacturer cannot legally export drugs to the United States.

Who Must Register

Any foreign establishment that manufactures, prepares, propagates, compounds, or processes a drug product intended for import into the US must register. This includes:

• Finished dosage form manufacturers
• Active pharmaceutical ingredient (API) manufacturers
• Contract manufacturers producing for a US-bound supply chain
• Repackers and relabelers
• Specification developers who outsource manufacturing but hold the product license

Establishments that perform only distribution functions (i.e., no manufacturing, repackaging, or relabeling) may not be required to register as manufacturers, but must still ensure their upstream suppliers are registered.

Registration Process via FURLS

Foreign establishments register through FDA's Unified Registration and Listing System (FURLS), accessible at fdaonline.center4drugeval.com. Registration requires:

• The establishment's physical address and contact information
• Name and contact information for a US agent (a person physically located in the US who acts as the FDA point of contact for the establishment)
• The owner/operator's name and address
• A listing of all drug products manufactured at the facility (drug listing)

The drug listing component is a parallel requirement under 21 USC 360 and 21 CFR Part 207. Every drug product manufactured at the registered facility must be listed — including: drug name, dosage form, route of administration, active ingredients and strengths, and NDC (National Drug Code) if applicable. Drug listings must be updated whenever a product is introduced, discontinued, or materially changed.

Annual Renewal Window

Foreign establishment registrations must be renewed annually between October 1 and December 31. Failure to renew within this window results in the registration lapsing — and a lapsed registration places the facility at risk of having its shipments refused admission at US ports of entry. FDA field personnel are instructed to flag shipments from facilities whose registration status is not current.

Verifying Supplier Registration

FDA's establishment registration database is publicly searchable at fda.gov/drugs/drug-approvals-and-databases/drug-establishments-current-registration-site. Before entering any pharmaceutical supply agreement, importers should search for the foreign facility and confirm: (1) the registration is current and active, (2) the facility address matches the physical manufacturing location, and (3) the relevant drug products appear in the facility's drug listing. Discrepancies between the registered address and actual manufacturing site are a common audit finding and a basis for import refusal.

---

FDA Prior Approval Requirements — NDA, ANDA, BLA

Establishment registration confirms who is manufacturing the drug. A separate, independent requirement is that the drug product itself must be legally marketed in the US — which generally requires an approved application. Importing a drug that lacks the required approval is importing an unapproved new drug, subject to refusal under 21 USC 381(a) and potentially FDA import alert IA 66-41.

New Drug Applications (NDA) and Abbreviated NDAs (ANDA)

For most finished pharmaceutical products, US marketing requires either a New Drug Application (NDA) under 21 USC 505(b) or an Abbreviated New Drug Application (ANDA) under 21 USC 505(j). The NDA pathway applies to novel drugs; the ANDA pathway applies to generics that demonstrate bioequivalence to a reference listed drug.

Critically, the NDA or ANDA approval specifies not just the product but the manufacturing site. If a drug product approved under NDA-123456 was approved for manufacture at Facility A, and a foreign manufacturer at Facility B begins producing the same drug without a Prior Approval Supplement (PAS) to amend the NDA to include Facility B, the product from Facility B is considered an unapproved drug — even if the manufacturing process is identical. This site-specificity in FDA approvals is a frequent compliance trap for importers who switch contract manufacturers without notifying the NDA/ANDA holder.

Biologics License Applications (BLA)

Biologic products — including vaccines, blood products, therapeutic proteins, and biosimilars — are regulated under the Public Health Service Act (42 USC 262) and require a Biologics License Application (BLA). The BLA must be approved before the biologic can be legally imported and marketed in the US. Biosimilars require either a standalone BLA or an abbreviated BLA demonstrating biosimilarity to a reference product.

Unlike small-molecule drugs, biologics are subject to extensive manufacturing process controls that are themselves part of the approved BLA. Process changes — even seemingly minor ones — can require BLA amendments. Importers of biologics from foreign manufacturers must ensure their suppliers are current on all required BLA supplements.

---

DEA Controlled Substance Import Requirements

Pharmaceutical products that contain controlled substances — substances listed in Schedules I through V under the Controlled Substances Act — are subject to a parallel regulatory framework administered by the Drug Enforcement Administration. DEA requirements are entirely independent of FDA requirements: a product with full FDA approval and a current establishment registration still requires separate DEA authorization to import if it contains a controlled substance.

DEA Importer Registration

Any US entity that imports controlled substances must hold a DEA importer registration. The application is submitted via DEA Form DEA-225 (Application for Registration). DEA evaluates applicants based on their history, state licensure, and demonstrated legitimate need for the controlled substance. Registration must be renewed annually.

DEA importer registrations are substance-specific — a registration that covers Schedule II opioid imports does not automatically cover Schedule II stimulant imports. Importers must ensure their registration covers each specific controlled substance they intend to import.

Import Declarations for Schedule I and II Substances

Before importing Schedule I or Schedule II controlled substances, importers must file an import declaration (DEA Form 357) with DEA. The declaration must be submitted prior to shipment and must specify: the substance, quantity, origin country, and foreign exporter. DEA reviews and either approves or denies the declaration. Importation cannot proceed until the declaration is approved.

DEA Form 357 filings require the importer to demonstrate that the quantity being imported does not exceed the importer's authorized import quota (for narcotic substances) and that the foreign exporter holds appropriate export authorization under their country's laws. DEA maintains relationships with competent authorities in major supplier countries to verify this.

Schedules III–V Controlled Substances

Schedule III, IV, and V controlled substances face less restrictive import requirements than Schedules I and II. Import declarations are required unless the quantity falls below DEA de minimis thresholds. However, the importer registration requirement applies to all schedules. Importers should review the specific requirements for each substance in 21 CFR Part 1312.

---

cGMP Compliance and FDA Inspections

Current Good Manufacturing Practice (cGMP) regulations set the minimum quality standards for pharmaceutical manufacturing. For finished dosage forms, the governing regulations are 21 CFR Part 210 (Current Good Manufacturing Practice in Manufacturing, Processing, Packing, or Holding of Drugs: General) and 21 CFR Part 211 (Current Good Manufacturing Practice for Finished Pharmaceuticals). For active pharmaceutical ingredients, FDA follows the ICH Q7 guidance (Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients), which is incorporated by reference into FDA's regulatory framework.

FDA Foreign Facility Inspections

FDA conducts foreign facility inspections at manufacturing sites that supply drugs to the US market. These inspections are classified into three outcome categories:

• No Action Indicated (NAI) — the facility is compliant; no significant violations observed. This is the desired outcome.
• Voluntary Action Indicated (VAI) — minor violations observed; FDA recommends voluntary corrective action. Does not typically affect import status, but should be monitored.
• Official Action Indicated (OAI) — significant violations found; FDA regulatory action is warranted. OAI typically leads to a Warning Letter, and often leads to the facility being placed on an import alert (DWPE status).

During an inspection, FDA investigators issue a Form 483 (Inspectional Observations) listing objectionable conditions they observed. A Form 483 is not itself a violation notice — it is a list of observations. The facility's response to Form 483 observations, and FDA's assessment of the adequacy of corrective actions, drives the ultimate classification of the inspection.

Risk-Based Inspection Scheduling

Since 2017, FDA has used a risk-based scheduling system to prioritize foreign facility inspections. Facilities are prioritized based on: import volume (higher volume = higher inspection priority), time since last inspection, prior compliance history, and product risk profile (sterile injectables carry higher risk than oral solid dosage forms). Facilities that have never been inspected are a priority for FDA's surveillance inspection program.

Importers sourcing from foreign facilities that have never been inspected by FDA, or that have not been inspected in several years, should understand this represents a latent compliance risk: an inspection triggered by a complaint, adverse event report, or routine surveillance could result in OAI classification and import alert placement with no advance warning.

---

FDA Import Alerts and DWPE Status

An FDA Import Alert is a public notice issued by FDA that instructs field personnel at US ports of entry to detain products from specific firms, specific countries, or entire product categories — without physical examination (DWPE). DWPE is the critical distinction: instead of inspecting each shipment before deciding whether to admit or refuse it, FDA field personnel automatically detain all shipments covered by an active import alert, placing the burden on the importer to overcome the presumption of violation.

Key Pharmaceutical Import Alerts

The following import alerts most commonly affect pharmaceutical importers:

Checking Import Alert Status

FDA's import alert database is publicly accessible at accessdata.fda.gov/cms_ia/ialist.html. Importers can search by firm name, country of origin, or product type to determine whether any relevant import alert is active. This check should be performed during supplier qualification — before any shipment is placed — and should be repeated periodically for active suppliers. Import alerts can be placed between shipments without notice to the importer.

Requesting Removal from an Import Alert

A firm placed on an import alert can seek removal by submitting a Request for Removal from Import Alert to FDA. The request must include documented evidence of corrective action that addresses the underlying violations. FDA's standard review period is approximately 60 days. For cGMP-related import alerts (IA 66-40), removal typically requires evidence of a successful re-inspection or a third-party audit accepted by FDA, along with resolution of all Form 483 observations and Warning Letter items.

Importers should understand that removal from an import alert is the foreign manufacturer's responsibility, not the importer's. However, importers bear the practical consequence of detained shipments during the remediation period. In supply-critical situations, importers may need to identify alternative qualified suppliers while their primary supplier works through the removal process.

---

HTS Classification for Pharmaceuticals

Pharmaceutical products are primarily classified in Chapter 30 of the Harmonized Tariff Schedule (HTS), titled "Pharmaceutical Products." Correct HTS classification determines both the applicable duty rate and which Partner Government Agency (PGA) messages CBP transmits to FDA during entry processing. Misclassification of pharmaceutical products can result in incorrect PGA message routing, which can delay FDA review and admissibility decisions.

Key HTS Headings in Chapter 30

The most commercially significant heading for pharmaceutical importers is HTS 3004 — medicaments consisting of mixed or unmixed products put up in measured doses or in forms or packings for retail sale. This heading covers the vast majority of finished pharmaceutical products and generally carries a 0% MFN duty rate. However, correct classification within 3004 requires understanding the subheading structure, which distinguishes products by active ingredient type (antibiotics, hormones, alkaloids, vitamins, etc.).

The 3003 vs. 3004 Distinction

A classification question that frequently arises in practice is whether a product belongs under 3003 (not in measured doses) or 3004 (in measured doses, retail form). The critical distinction is dosage form and packaging: 3004 covers products that are put up in forms or packaging for retail sale (unit-dose blisters, labeled vials, retail bottles) or in measured doses (specific mg per tablet, per mL, per patch). Bulk pharmaceutical preparations that require further processing before retail packaging generally fall under 3003. The duty rates are both typically 0%, so the distinction rarely affects duty liability — but it does affect FDA PGA message routing and regulatory treatment.

---

Active Pharmaceutical Ingredients (APIs) — Special Considerations

Active pharmaceutical ingredients are the biologically active components of finished drug products. They are not finished drugs themselves, but they are regulated as drug components under the FD&C Act and must comply with FDA's API-specific cGMP standards. API importation presents distinct compliance considerations from finished dosage form importation.

HTS Classification for APIs

APIs are generally not classified under Chapter 30 of the HTS. Most APIs are organic chemical compounds and are classified under Chapter 29 (Organic Chemicals) of the HTS. Chapter 29 covers a broad range of chemical compounds, and the specific 10-digit subheading for any given API depends on its chemical structure and category.

Common API HTS categories and duty ranges:

• Antibiotics (2941) — Free to 3.7% MFN
• Vitamins (2936) — Free to 6% MFN
• Hormones (2937) — Free to 3.7% MFN
• Alkaloids (2939) — Free to 3.7% MFN
• Heterocyclic compounds (2933) — Free to 6.5% MFN

Unlike finished pharmaceuticals under Chapter 30 (which are almost universally at 0% MFN), some API subheadings in Chapter 29 carry nonzero MFN duty rates. Understanding the HTS classification for your specific API affects landed cost calculations.

FDA Registration for API Manufacturers

Foreign API manufacturers are subject to the same 21 CFR Part 207 registration requirement as finished dosage form manufacturers. API manufacturing facilities must register with FDA, list their API products, and renew annually during the October–December window. FDA inspects API manufacturing facilities separately from finished dosage form facilities, and API facilities are subject to the ICH Q7 cGMP standards.

Drug Master Files (DMFs)

Foreign API manufacturers often support their US customers' NDA/ANDA applications through Drug Master Files (DMFs), submitted directly to FDA under 21 CFR Part 314.420. A Type II DMF covers drug substances (APIs) and provides confidential manufacturing information that FDA can reference when reviewing an applicant's NDA or ANDA without disclosing the API manufacturer's proprietary process details.

For importers sourcing APIs for use in US drug products, confirming that the API manufacturer has an active Type II DMF filed with FDA — and that the DMF has been referenced and accepted in at least one approved NDA or ANDA — is a meaningful indicator of the manufacturer's FDA engagement and cGMP status. An API manufacturer without any DMF history has received less FDA scrutiny and represents higher regulatory risk.

---

Common Compliance Mistakes

Pharmaceutical import compliance failures are costly: detained shipments, import refusals, and FDA enforcement actions can disrupt supply chains, trigger product shortages, and expose importers to significant liability. These are the most common mistakes that experienced importers make:

---

Frequently Asked Questions